Biotech start-up Covimro Ltd said on Wednesday that its food-grade compound Covimro is effective against Coronavirus based on tests.
Based in the UK, the company added the Covimro has been shown to be equally effective against other viruses as demonstrated in recent scientific studies. In March 2021, Covimro was tested for antiviral efficacy against Lentivirus/HIV with a Luciferase Assay.
In conjunction with the trials, the results show a three log reduction in viral titre at all concentrations tested. This preliminary data warrants further investigation in to the Covimro effect, said Dr Senthil Chinnakannan, a molecular virologist at the University of Oxford.
According to the company, the protein spikes naturally evolve and change over time, resulting in mutations that lead to new strains, which put pressure on vaccines as well as the requirement for booster doses . With new Covid strains continually emerging around the world, the growing reality is that Covid is likely to remain in the world for many years to come.
Currently, the company is in discussions with international distribution partners for an upcoming launch of its consumer goods products.
Pfizer reports positive Phase 3 data for ABRYSVO in adults at risk for RSV disease
Clover Bio announces SCB-1019 vaccine candidate Phase I trial data in initial young adult cohort
Sanofi launches Verorab for rabies prophylaxis in UK
BioVaxys expands patent portfolio for DPX delivery platform and advances DPX SurMAGE
YS Biopharma repays USD40m loan facility
Kintara Therapeutics and TuHURA Biosciences to merge
VGXI names new chief accounting officer
Moderna reports positive interim results from next-generation COVID-19 vaccine trial
Valneva launches Phase 1 trial for next-generation Zika vaccine
Circio Holding ASA confirms licensing deal with IOVaxis Therapeutics in China and Singapore
Everest Medicines names new chief medical officer and chief product officer
Pfizer's PREVENAR 20 gains European Commission approval for paediatric pneumococcal vaccine